Dare Bioscience (DARE) and its partner Strategic Science & Technologies said Monday they will submit a protocol and statistical analysis plan to the US Food and Drug Administration in Q1 for a phase 3 study of sildenafil cream, 3.6%, an investigational treatment for female sexual arousal disorder.
The companies said they plan to launch a phase 3 study of the topical drug in mid-2025.
The plan reflects FDA feedback for safety and efficacy, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。